Cargando…

eIF6 coordinates insulin sensitivity and lipid metabolism by coupling translation to transcription

Insulin regulates glycaemia, lipogenesis and increases mRNA translation. Cells with reduced eukaryotic initiation factor 6 (eIF6) do not increase translation in response to insulin. The role of insulin-regulated translation is unknown. Here we show that reduction of insulin-regulated translation in...

Descripción completa

Detalles Bibliográficos
Autores principales: Brina, Daniela, Miluzio, Annarita, Ricciardi, Sara, Clarke, Kim, Davidsen, Peter K., Viero, Gabriella, Tebaldi, Toma, Offenhäuser, Nina, Rozman, Jan, Rathkolb, Birgit, Neschen, Susanne, Klingenspor, Martin, Wolf, Eckhard, Gailus-Durner, Valerie, Fuchs, Helmut, Hrabe de Angelis, Martin, Quattrone, Alessandro, Falciani, Francesco, Biffo, Stefano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Pub. Group 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4595657/
https://www.ncbi.nlm.nih.gov/pubmed/26383020
http://dx.doi.org/10.1038/ncomms9261
Descripción
Sumario:Insulin regulates glycaemia, lipogenesis and increases mRNA translation. Cells with reduced eukaryotic initiation factor 6 (eIF6) do not increase translation in response to insulin. The role of insulin-regulated translation is unknown. Here we show that reduction of insulin-regulated translation in mice heterozygous for eIF6 results in normal glycaemia, but less blood cholesterol and triglycerides. eIF6 controls fatty acid synthesis and glycolysis in a cell autonomous fashion. eIF6 acts by exerting translational control of adipogenic transcription factors like C/EBPβ, C/EBPδ and ATF4 that have G/C rich or uORF sequences in their 5′ UTR. The outcome of the translational activation by eIF6 is a reshaping of gene expression with increased levels of lipogenic and glycolytic enzymes. Finally, eIF6 levels modulate histone acetylation and amounts of rate-limiting fatty acid synthase (Fasn) mRNA. Since obesity, type 2 diabetes, and cancer require a Fasn-driven lipogenic state, we propose that eIF6 could be a therapeutic target for these diseases.